Document Detail

Intracoronary glycoprotein IIb/IIIa inhibitor infusion via a perfusion coronary catheter to decrease thrombus burden: Results from the ClearWay™ Multicenter Registry.
MedLine Citation:
PMID:  23375788     Owner:  NLM     Status:  Publisher    
OBJECTIVES: This multicenter registry aimed to assess the ClearWay™ (CW) perfusion catheter in reduction of thrombus burden and improvement of the coronary flow during percutaneous coronary intervention (PCI). BACKGROUND: The presence or development of thrombus during PCI is associated with poor prognosis. METHODS: The utility of the CW perfusion catheter was assessed in patients who presented with intracoronary thrombus and were subjected to PCI. Data were collected by online survey from 15 US sites. Angiographic assessment of the coronary thrombus burden and the coronary flow after intracoronary infusion of glycoprotein (GP) IIb/IIIa inhibitors via the CW catheter was evaluated at baseline, immediately after infusion, and at the end of the procedure. The cohort included 102 patients; 71.6% presented with ST-elevation myocardial infarction (MI), 21.6% with non-ST-elevation MI, 5.9% with stable angina pectoris, and 2.9% with silent ischemia. The mean cohort age was 59.9±14.5years and comprised mostly of men (72.5%). RESULTS: GP IIb/IIIa inhibitors were infused via the CW catheter on average 1.1±0.3 times, with a mean pressure of 4.2±2.7atm and a mean infusion time of 55±55s. Following the infusion, Thrombolysis In Myocardial Infarction (TIMI) flow improved by 1° in 71 patients (69.6%) and by 2° in 51 patients (50%), while visible thrombus was reduced by 52% (p<0.001). In the final angiogram, TIMI flow was restored in 90.2% and clearance of a visible thrombus was obtained in 91.8% of the lesions. CONCLUSION: Intracoronary infusion of GP IIb/IIIa inhibitors via the perfusion CW catheter is associated with significant reduction in thrombus burden and with improvement of the coronary flow in patients presenting or developing thrombus burden during PCI.
Gabriel Maluenda; Byron C Sizemore; George Revtyak; Nick Cavros; Bradley B McElroy; Dilip S Arora; Al Deibele; Satyaprakash Makam; Itsik Ben-Dor; Rebecca Torguson; Ron Waksman;
Related Documents :
17556168 - Severe coronary artery calcifications are associated with ischemia in patients undergoi...
23453458 - Characteristics and in-hospital outcomes of patients with non-st-segment elevation myoc...
24848778 - Usefulness of stress myocardial perfusion imaging and baseline clinical factors for pre...
24774028 - Should angiotensin-converting enzyme inhibitors be continued over the long term in pati...
19840558 - The chemokine network in relation to infarct size and left ventricular remodeling follo...
7151098 - Experimental myocardial ischemia ii: radiographic contrast media toxicity.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-29
Journal Detail:
Title:  Cardiovascular revascularization medicine : including molecular interventions     Volume:  -     ISSN:  1878-0938     ISO Abbreviation:  Cardiovasc Revasc Med     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-2-4     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101238551     Medline TA:  Cardiovasc Revasc Med     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012. Published by Elsevier Inc.
Washington Hospital Center, Washington, DC 20010, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Dynamic balance during gait in children and adults with Generalized Joint Hypermobility.
Next Document:  The relationship between peak knee extension at heel-strike of walking and the location of thickest ...